Magnesium Sulfate low dose — Competitive Intelligence Brief

Magnesium Sulfate low dose (Magnesium Sulfate low dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Electrolyte supplement / anticonvulsant. Area: Neurology, Obstetrics, Cardiovascular.

phase 3 Electrolyte supplement / anticonvulsant NMDA receptor, voltage-gated calcium channels Neurology, Obstetrics, Cardiovascular Small molecule

Target snapshot

Magnesium Sulfate low dose (Magnesium Sulfate low dose) — University of Monastir. Magnesium sulfate acts as a physiological calcium antagonist and NMDA receptor antagonist, reducing neuronal excitability and vascular smooth muscle contractility.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Magnesium Sulfate low dose TARGET	Magnesium Sulfate low dose	University of Monastir	phase 3	Electrolyte supplement / anticonvulsant	NMDA receptor, voltage-gated calcium channels
Perioperative magnesium sulfate	Perioperative magnesium sulfate	Instituto Mexicano del Seguro Social	marketed	Electrolyte supplement / NMDA receptor antagonist	NMDA receptor, voltage-gated calcium channels
Magnesium Sulfate, Heptahydrate	Magnesium Sulfate, Heptahydrate	University of Utah	marketed	Electrolyte supplement / anticonvulsant / bronchodilator	NMDA receptor, voltage-gated calcium channels
Magnesium sulfate 33% solution	Magnesium sulfate 33% solution	The Baruch Padeh Medical Center, Poriya	marketed	Electrolyte supplement / anticonvulsant	Voltage-gated calcium channels, NMDA receptors
Magnesium sulfate IV	Magnesium sulfate IV	University of Liege	marketed	Electrolyte supplement / anticonvulsant	NMDA receptor, L-type calcium channels
Magnesium sulphate.	Magnesium sulphate.	Ain Shams University	marketed	Electrolyte supplement / anticonvulsant / tocolytic agent	Voltage-gated calcium channels, NMDA receptor
Magnesium Sulfate Infusion	Magnesium Sulfate Infusion	Ondokuz Mayıs University	marketed	Electrolyte supplement / anticonvulsant / tocolytic agent	NMDA receptor antagonist; calcium channel modulator

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Electrolyte supplement / anticonvulsant class)

1. The Baruch Padeh Medical Center, Poriya · 1 drug in this class
2. University Hospitals Cleveland Medical Center · 1 drug in this class
3. University of Liege · 1 drug in this class
4. University of Monastir · 1 drug in this class